Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same
The present invention relates to an injenane-type diterpene compound derived from Euphorbia kansui Liou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.
1. A method for treating HIV (human immunodeficiency virus) infectious diseases, comprising administering a pharmaceutical composition to a subject having an HIV infectious disease occurrence with a therapeutically effective dose, wherein the composition comprises a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein, in the formula,
R 1 is H, R 2 is H, R 3 is OCO—(CH 2 ) 10 —CH 3 and R 4 is CO—CH(CH 3 )—CH(CH 3 ) 2 ;
R 1 is CO—CH(CH 3 )—CH(CH 3 ) 2 , R 2 is H, R 3 is OCO—(CH 2 ) 10 —CH 3 and R 4 is H;
R 1 is H, R 2 is OCO—(CH 2 ) 8 —CH 3 , R 3 is H and R 4 is H; or
R 1 is CO(CH═CH)—(CH 2 ) 4 —CH 3 , R 2 is OAc, R 3 is H and R 4 is H.
2. A method for ameliorating HIV (human immunodeficiency virus) infectious diseases, comprising administering a health functional food to a subject having an HIV infectious disease occurrence, wherein the health functional food comprises a compound represented by Chemical Formula 2 or a sitologically acceptable salt thereof as an active ingredient:
wherein, in the formula,
R 1 is H, R 2 is H, R 3 is OCO—(CH 2 ) 10 —CH 3 and R 4 is CO—CH(CH 3 )—CH(CH 3 ) 2 ;
R 1 is CO—CH(CH 3 )—CH(CH 3 ) 2 , R 2 is H, R 3 is OCO—(CH 2 ) 10 —CH 3 and R 4 is H;
R 1 is H, R 2 is OCO—(CH 2 ) 8 —CH 3 , R 3 is H and R 4 is H; or
R 1 is CO(CH═CH)—(CH 2 ) 4 —CH 3 , R 2 is OAc, R 3 is H and R 4 is H.
3. A method of enhancing production of interferon-gamma in a subject in need thereof, comprising administering a composition to the subject, wherein the composition comprises a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein, in the formula,
R 1 is H, R 2 is H, R 3 is OCO—(CH 2 ) 10 —CH 3 and R 4 is CO—CH(CH 3 )—CH(CH 3 ) 2 ;
R 1 is CO—CH(CH 3 )—CH(CH 3 ) 2 , R 2 is H, R 3 is OCO—(CH 2 ) 10 —CH 3 and R 4 is H;
R 1 is H, R 2 is OCO—(CH 2 ) 8 —CH 3 , R 3 is H and R 4 is H;
R 1 is CO(CH═CH)—(CH 2 ) 4 —CH 3 , R 2 is OAc, R 3 is H and R 4 is H; or
R 1 is CO—CH(CH 3 )—CH(CH 3 ) 2 , R 2 is OH, R 3 is OCO—(CH 2 ) 10 —CH 3 and R 4 is H.